You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: June 14, 2025

Details for Patent: 11,013,733


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 11,013,733 protect, and when does it expire?

Patent 11,013,733 protects REZLIDHIA and is included in one NDA.

This patent has eighteen patent family members in fifteen countries.

Summary for Patent: 11,013,733
Title:Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1)
Abstract:Patients diagnosed with a cancer harboring an IDH-1 mutation can be treated by the administration of a therapeutically effective amount of a pharmaceutical composition comprising Compound 1, a selective inhibitor of 2-HG production from mIDH-1 enzymes including the R132 mutations R132C, R132H, R132L, R132G, and R132S.
Inventor(s):Susan Ashwell, Blythe Thomson, Patrick F. Kelly, Alan Collis, Jeff Davis, Duncan Walker, Wei Lu
Assignee:Forma Therapeutics Inc
Application Number:US16/431,588
Patent Claim Types:
see list of patent claims
Patent landscape, scope, and claims:

Understanding the Scope and Claims of a U.S. Patent: A Detailed Analysis of United States Patent 11,013,733

Introduction

When analyzing a U.S. patent, such as United States Patent 11,013,733, it is crucial to delve into the patent's scope, claims, and the broader patent landscape. This analysis helps in understanding the patent's validity, its impact on innovation, and its potential for litigation or licensing.

What is a Patent?

A patent is a government grant that gives the inventor exclusive rights to make, use, and sell an invention for a specified period, typically 20 years from the filing date of the patent application. The U.S. Patent and Trademark Office (USPTO) is responsible for granting U.S. patents and registering trademarks[2].

Determining Inventorship

Before diving into the patent's scope and claims, it is essential to understand who the inventors are. U.S. patent law requires that only the "true and only" inventors be listed on the patent application. This involves identifying those who conceived the idea or subject matter of the patent claims. Conception is defined as the formation in the mind of the inventor of a definite and permanent idea of the complete and operative invention[5].

Patent Scope and Claims

The scope of a patent is a critical aspect that defines the boundaries of what is protected. Here are some key points to consider:

Independent Claim Length and Count

Research has shown that the scope of a patent can be measured using simple metrics such as independent claim length and independent claim count. These metrics have explanatory power for several correlates of patent scope, including patent maintenance payments, forward citations, and the breadth of patent classes. Narrower claims at publication are associated with a higher probability of grant and a shorter examination process[3].

Examination Process

The examination process at the USPTO tends to narrow the scope of patent claims. This is evident from the changes in claim length and count during the examination process. Longer examination durations often result in more significant narrowing of the claims[3].

Patent Allowance Rates

Understanding the probability of receiving a U.S. patent is vital. Studies have analyzed patent applications filed between 1996 and 2005 to estimate allowance rates. There are three key measures:

  • First-action allowance rate: The proportion of progenitor applications allowed without further examination.
  • Progenitor allowance rate: The proportion of progenitor applications allowed without any continuation procedure.
  • Family allowance rate: The proportion of progenitor applications that produce at least one patent, including outcomes of continuation applications[4].

Geographic and Sectoral Analysis

Patents can be analyzed by geography and economic sector. For instance, USPTO patents can be shown by the residence of the inventor or by the sector of the owner. This helps in understanding patterns and trends in patenting activity both domestically and internationally[1].

Classification and Fractional Count

Patents are classified using various systems, such as the International Patent Classification (IPC) codes. The fractional count of inventors is used to allocate patents to countries, especially when the first granted patent in a family does not list inventor countries. This method ensures more complete information for a large number of countries[1].

Example: United States Patent 11,013,733

To illustrate the above points, let's consider a hypothetical analysis of United States Patent 11,013,733.

Patent Claims

  • Independent Claims: Analyze the length and count of independent claims to understand the patent's scope. Narrower claims might indicate a higher probability of grant and shorter examination process.
  • Dependent Claims: Dependent claims further define the scope by adding additional limitations to the independent claims.

Examination History

  • Review the examination history to see if the claims were narrowed during the process. This can indicate the patent's validity and the examiner's scrutiny.

Inventorship

  • Verify the listed inventors to ensure they are the true and only inventors. Incorrect or incomplete inventorship can lead to patent invalidation[5].

Geographic and Sectoral Analysis

  • Identify the residence of the inventors and the sector of the patent owner to understand the patent's geographical and economic context.

Impact on Innovation

The scope and claims of a patent can significantly impact innovation. Here are some considerations:

Licensing and Litigation

  • Broader patents with unclear or overly broad claims can lead to increased licensing and litigation costs, potentially diminishing innovation incentives[3].

Forward Citations

  • Patents with narrower claims and higher forward citations may indicate a stronger contribution to the field, encouraging further innovation.

Key Takeaways

  • Patent Scope: Measured using metrics like independent claim length and count, it defines the boundaries of what is protected.
  • Examination Process: Tends to narrow the scope of patent claims, with longer durations resulting in more significant narrowing.
  • Inventorship: Correct determination of inventorship is crucial to avoid patent invalidation.
  • Geographic and Sectoral Analysis: Helps in understanding patterns and trends in patenting activity.
  • Impact on Innovation: The scope and claims can influence licensing, litigation, and the overall innovation landscape.

FAQs

  1. What is the significance of independent claim length and count in patent scope?

    • These metrics help measure the scope of a patent and have explanatory power for several correlates of patent scope, such as patent maintenance payments and forward citations[3].
  2. How does the USPTO determine the country of origin for a patent?

    • The USPTO uses a fractional count of inventors listed on the first granted patent in a family or the earliest patent document in the family that lists inventor locations[1].
  3. What are the consequences of incorrect inventorship on a patent?

    • Incorrect or incomplete inventorship can lead to patent invalidation, especially if there is deceptive intent. Corrections can be made, but fraudulent intent renders the patent unenforceable[5].
  4. How does the examination process affect patent claims?

    • The examination process tends to narrow the scope of patent claims, with longer examination durations resulting in more significant narrowing[3].
  5. What is the importance of forward citations in patent analysis?

    • Forward citations indicate the impact of a patent on subsequent innovations and can be a measure of the patent's contribution to the field.

Sources

  1. National Science Foundation. Invention, Knowledge Transfer, and Innovation. 2024.
  2. USA.gov. U.S. Patent and Trademark Office (USPTO).
  3. SSRN. Patent Claims and Patent Scope. 2016.
  4. Yale Journal of Law and Technology. What Is the Probability of Receiving a US Patent?.
  5. Oregon State University. Determining Inventorship for US Patent Applications.

More… ↓

⤷  Try for Free


Drugs Protected by US Patent 11,013,733

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Rigel Pharms REZLIDHIA olutasidenib CAPSULE;ORAL 215814-001 Dec 1, 2022 RX Yes Yes ⤷  Try for Free ⤷  Try for Free A METHOD OF TREATING A CANCER CHARACTERIZED BY AN IDH1 MUTATION WHERE THE CANCER IS ACUTE MYELOID LEUKEMIA (AML) ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 11,013,733

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Denmark 3720442 ⤷  Try for Free
European Patent Office 3720442 ⤷  Try for Free
European Patent Office 4215197 ⤷  Try for Free
Spain 2941079 ⤷  Try for Free
Finland 3720442 ⤷  Try for Free
Croatia P20230168 ⤷  Try for Free
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.